Overview

Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis

Status:
Recruiting

Trial end date:
2022-08-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to determine if a single dose of nerinetide can reduce neurological disability in people who have had a stroke and are selected for endovascular therapy without the use of a tissue plasminogen activator (alteplase, tenecteplase, or equivalent).

Phase:

Phase 3

Details

Lead Sponsor:

NoNO Inc.

Collaborator:

University of Calgary